利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.037 秒)

    Pyridothienopyrimidine Derivatives
    1.
    发明申请
    Pyridothienopyrimidine Derivatives 审中-公开
    吡啶并噻吩并嘧啶衍生物

    公开(公告)号：US20080207645A1

    公开(公告)日：2008-08-28

    申请号：US11791451

    申请日：2005-11-30

    申请人： Luis Miguel Pages Santacana ,  Joan Taltavull Moll ,  Jordi Gracia Ferrer

    发明人： Luis Miguel Pages Santacana ,  Joan Taltavull Moll ,  Jordi Gracia Ferrer

    IPC分类号： A61K31/519 ,  A61P19/02

    CPC分类号： C07D495/22 ,  A61K31/519

    摘要： A pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt or N-oxide thereof are disclosed, as well as pharmaceutical compositions comprising said compounds and methods of treatment or prevention of a pathological condition or disease susceptible to amelioration by inhibition of phosphodiesterase 4 using said compounds are disclosed.

    摘要翻译： 公开了式（I）的吡啶并[3'，2'：4,5]噻吩并[3,2-d]嘧啶衍生物或其药学上可接受的盐或N-氧化物，以及包含所述化合物和 公开了通过使用所述化合物抑制磷酸二酯酶4来治疗或预防易于改善的病理状况或疾病的方法。

    Pyrido[3' ,2':4,5]Furo[3,2-d]Pyrimidine Derivatives
    2.
    发明申请
    Pyrido[3' ,2':4,5]Furo[3,2-d]Pyrimidine Derivatives 审中-公开

    公开(公告)号：US20080221096A1

    公开(公告)日：2008-09-11

    申请号：US11996781

    申请日：2006-07-21

    申请人： Joan Taltavull Moll ,  Luis Miguel Pages Santacana

    发明人： Joan Taltavull Moll ,  Luis Miguel Pages Santacana

    IPC分类号： A61K31/5377 ,  C07D239/70 ,  C07D295/00 ,  A61P17/00 ,  A61P1/00 ,  A61P11/00 ,  A61K31/519

    CPC分类号： C07D491/14

    摘要： The present disclosure relates to a pyridofuropyrimidine derivative of formula (I): whereinG1 is a group chosen from —CR6R7— and —O— wherein R6 and R7 are independently chosen from hydrogen atoms and C1-4 alkyl groups; R1 and R2 are independently chosen from hydrogen atoms and C1-4 alkyl groups; R3 is chosen from C1-4 alkyl, C1-4 alkoxy, amino, hydroxy, mono-C1-4alkylamino, di-C1-4alkylamino, C3-8cycloalkylamino, aryl, heteroaryl and saturated N-containing heterocyclyl groups which are bound to the pyridine ring through their nitrogen atom, all of them being optionally substituted by one or more substituents chosen from halogen atoms and hydroxy, C1-4 alkyl, C1-4alkoxy-C1-4alkyl, aryl-C1-4alkyl, —O(CO)OR8, C1-4 alkoxy, —(CO)NR8R9, —CN, —CF3, —NR8R9, —SR8 and —SO2NH2 groups wherein R8 and R9 are each independently chosen from a hydrogen atom or a C1-4 alkyl group; R4 and R5 are independently chosen from hydrogen atoms, C1-4alkyl groups, hydroxyl-C1-4alkyl groups and groups of formula (II): wherein p and q are integers chosen from 0, 1, 2 and 3; A is either a direct bond or a group chosen from —CONR14—, —NR14CO—, —O—, —COO—, —OCO—, —S—, —SO— and —SO2—, wherein each R10, R11, R12, R13 and R14 are independently chosen from a hydrogen atom and a C1-4alkyl group and G2 is chosen from aryl, heteroaryl and heterocyclyl groups; wherein the group G2 is optionally substituted by one or more substituents chosen from halogen atoms and C1-4alkyl, hydroxy, oxo, C1-4alkoxy-C1-4alkyl, aryl-C1-4alkyl, —(CO)OR16, C1-4alkoxy, —(CO)NR16R17, —CN, —CF3, —NR16R17—SR16 and —SO2NH2 groups; wherein R16 and R17 each independently chosen from hydrogen atom and a C1-4alkyl group and the pharmaceutically acceptable salts and N-oxides thereof.